Whitepaper: Opportunities in preclinical development
This whitepaper explains how you can find ways to optimise the holistic preclinical development process...
List view / Grid view
This whitepaper explains how you can find ways to optimise the holistic preclinical development process...
Researchers have now for the first time succeeded in converting skin cells into pluripotent stem cells by activating the cell's own genes...
Results suggest an approach that could be tested for treating people with heart failure...
A new study has shown that an experimental drug known as AZ32 significantly extends the survival of glioblastoma multiforme, the most common and deadly form of brain cancer...
Researchers have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone.
This webinar focused on a recent study evaluating a cohort of head and neck squamous cell carcinoma (HNSCC) patient tumours treated with anti-PD1 using CANscript™.
The Nobel Prize-winning observations and discoveries of John B. Gurdon and Shinya Yamanaka have ignited an explosion of excitement around the potential use of stem cells in research and treatment of human disease.
Progress in stem cell research and its translation to medicine is the focus of the International Society for Stem Cell Research annual meeting 20-23 June at the Melbourne Convention & Exhibition Centre in Melbourne, Australia.
This webinar, supported by Tecan, focused on the automated assessment of liver and cardiac toxicities in lead optimisation, using biochemical and human iPS cell assays.
Human primary hepatocytes (hpheps) are the gold standard for in vitro evaluation of drug metabolism, drug-drug interactions, and metabolic disease research. However, hpheps don’t survive in standard 2D culture for very long – no longer than two or three days.
Human primary hepatocytes (hphep cells) are the gold standard for in vitro evaluation of drug metabolism, drug-drug interactions, safety assessment of drug candidates, and disease modeling.
Despite their vast therapeutic potential in such areas as cell therapy and tissue engineering, stem cells have yet to live up to their original hype and demonstrate widespread clinical success.
The human body’s blood stem cells produce approximately 10 billion new white blood cells – termed immune cells – every day. Scientists in the U.S. have now discovered that some blood stem cells pick up the slack should any others fail to achieve these levels.
In this issue: urine-derived stem cells offer an innovative platform for drug testing and disease modelling, a paradigm shift in translational stem cell research, and the role of biomaterials in stem cell-based regenerative medicine.
In this issue: the positive impact of genomics on drug discovery, development and deployment, the confluence of biology and technology, and Artificial Intelligence: harnessing the potential to drive progress in drug discovery promises much for phenotypic drug discovery